Oncology On The Go

In a cobranded episode between Oncology On the Go , hosted by CancerNetwork®, and the American Society for Transplantation and Cellular Therapy (ASTCT)’s program ASTCT Talks , an expert panel explored when early antibiotic de-escalation may be feasible for pediatric populations who undergo hematopoietic cell transplantation. The panel was hosted by Diego R. Hijano, MD, MSc, who was joined by his c...

In September 2026, the FDA granted accelerated approval to sevabertinib (Hyrnuo) as a frontline treatment option for patients with locally advanced or metastatic nonsquamous non–small cell lung cancer (NSCLC) harboring HER2 tyrosine kinase domain (TKD)–activating mutations. The decision expanded sevabertinib’s indication from its accelerated approval in November 2025 as a therapy for patients who...

In this episode of Oncology On the Go , Daniel C. McFarland, DO, spoke with Yesne Alici, MD, who oversees Memorial Sloan Kettering Cancer Center (MSKCC)’s medical aid in dying (MAID) program. Together, they explored what MAID means for oncology practice now that it is legal in New York State. Alici defined MAID as the legal practice in which a terminally ill, capacitated adult with a life expectan...

At the 2026 Society of Hematologic Oncology (SOHO) Annual Meeting, CancerNetwork® sat down with a variety of experts to discuss the latest data and emerging trends surrounding the management of different hematologic malignancies. Speakers and presentations covered everything from second primary malignancy risks to novel clinical trial findings across lymphoma, myelodysplastic syndrome (MDS), leuke...

The treatment paradigm for non–muscle invasive bladder cancer (NMIBC) has shifted considerably since the FDA established a formal definition of Bacillus Calmette-Guérin (BCG)–unresponsive disease, opening the door to a wave of new intravesical and gene therapies, according to Saum Ghodoussipour, MD. In a conversation with CancerNetwork® on the Oncology On the Go podcast, Ghodoussipour, director of...

In August 2026, the FDA granted accelerated approval to iberdomide (Zenbexus) in combination with daratumumab and hyaluronidase-fihj (Darzalex Faspro) and dexamethasone for patients with relapsed/refractory multiple myeloma. The agency’s decision represents the first approval of a CELMoD, a more potent, target-specific successor to immunomodulatory drugs (IMiDs), according to Surbhi Sidana, MD. In...

Wellness and burnout are often treated as 2 ends of the same seesaw: add enough yoga, sleep, and time off, and the scale tips back toward balance. In this conversation, Daniel C. McFarland, DO, and Xiomara Rocha-Cadman, MD, argue that this framing misses what actually drives distress in oncology. Drawing on years of clinical and mentorship experience tracing back to Memorial Sloan Kettering Cancer...

In this episode of Oncology On the Go , CancerNetwork® spoke with Frank McCormick, PhD, about the arc of KRAS-targeted drug development over his 40-year career. He explained why KRAS was long considered “undruggable.” He walked through the origins of the National Cancer Institute’s RAS Initiative, which he helped lead starting in 2013, and how that effort produced several of the drugs now advancin...

In this second installment of their conversation on depression in oncology, Daniel C. McFarland, DO, and Boris Kiselev, MD, moved from diagnosis, covered in Part 1, into treatment. The discussion opened with the differential diagnoses that need to be ruled out before starting therapy: delirium, bipolar disorder, medical conditions such as endocrinopathies and severe anemia, and neurocognitive issu...

In a cobranded episode between Oncology On the Go, hosted by CancerNetwork®, and the American Society for Transplantation and Cellular Therapy’s (ASTCT) program ASTCT Talks, Terri Lynn Shigle, PharmD, BCOP, hosted Vinita Pai, PharmD, MS, BCPPS, who spoke about the use of CAR T-cell therapy for pediatric patients, focusing on acute lymphoblastic leukemia (ALL). After a brief overview of progress in...

In the newest edition of Oncology On the Go, Joshua Richter, MD, and Marco Davila, MD, PhD, spoke about the current multiple myeloma treatment landscape and highlighted practical considerations for administering CAR T-cell therapy to patients. Their discussion touched upon several critical subtopics ranging from optimizing operational and referral workflows to dismantling barriers to treatment acc...

At the 2026 National ICE-T Conference in Orlando, CancerNetwork® sat down with a variety of expert researchers and clinicians to discuss the latest developments in immune effector therapy across different hematologic oncology populations. Sessions at the meeting covered practical considerations for integrating CAR T-cell therapies, bispecific antibodies, and other modalities into the treatment of...

Following the FDA approval of allogeneic regulatory T cell–containing immunotherapy with hematopoietic stem and progenitor cell (HSPC) and T cells-vldq (Tregzi; Orca-T), CancerNetwork® spoke with Wendy Stock, MD, about what this decision means for the treatment of patients undergoing hematopoietic stem cell transplantation for different hematologic malignancies. Additionally, she discussed how thi...

Experts discuss diagnosing and treating insomnia in patients with cancer through methods like sleep hygiene, CBT-I, and pharmacotherapy. Insomnia is one of the most common symptoms oncologists are asked to manage, yet it’s often treated reactively with medication rather than through a structured, history-driven approach. In this episode of Oncology On the Go , Daniel C. McFarland, DO, sat down wit...

In this episode of Oncology On the Go , CancerNetwork® spoke with Kim Stravers, an International End-of-Life Doula Association (INELDA)–certified end-of-life doula, educator, and trainer based in the Phoenix Valley, to explore how death doulas support patients with cancer and their families across all stages of the disease trajectory. Stravers opened by defining the scope of end-of-life doula work...

Experts discuss the evolving frontline CML treatment landscape, the impact of asciminib, and clinical strategies for achieving treatment-free remission. Once considered a terminal diagnosis, chronic myeloid leukemia (CML) in chronic phase has been fundamentally rewritten as a highly manageable chronic condition. In this episode of Oncology on the Go , Joshua Zeidner, MD, and Jorge E. Cortes, MD, s...

In this episode of Oncology On the Go, CancerNetwork® joined Matthew Matasar, MD, chief of the Division of Blood Disorders at Rutgers Cancer Institute/Jack & Sheryl Morris Cancer Center, and professor of medicine at Rutgers Robert Wood Johnson Medical School, as he dove into the practice-changing data reshaping the management of aggressive and indolent B-cell lymphomas. Fresh off the presentat...

In a special edition of Oncology On the Go, Chinmay Jani, MD, joined CancerNetwork® in the studio to speak about different research initiatives he is involved with across precision oncology. He discussed ongoing work dedicated to validating and applying artificial intelligence (AI)–based tools in clinical work as well as overcoming immunotherapy resistance among patients with lung cancer. Jani, ch...

Cancer is never convenient, and it never arrives when a patient is truly prepared, according to Daniel C. McFarland, DO, who began the most recent episode of Oncology On the Go with this sentiment. When individuals enter the high-stakes, highly coordinated world of oncology, they do so under extreme duress, often presenting the versions of themselves that are most under stress. In this environment...

In a live X Spaces discussion hosted by CancerNetwork® in collaboration with the American Society for Transplantation and Cellular Therapy (ASTCT), Marc J. Braunstein, MD, PhD, and Sofia Zahid, MD, highlighted noteworthy presentations and abstracts in hematologic oncology at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. Together, they discussed the data that may shake up cl...

In a conversation with CancerNetwork®, Nathan Goodyear, MD , spoke about the role that exercise and lifestyle intervention can play in the treatment of patients with cancer. He described how prescribed exercise may serve as a biologically interventional therapy that can help prolong longevity, reduce the risk of recurrence; and supplement the efficacy of standard therapeutic approaches like chemot...

In a recent interview with CancerNetwork®, Nicholas Hornstein, MD, PhD, an assistant professor at the Donald and Barbara Zucker School of Medicine of Hofstra University and Northwell Health, discussed emerging data and clinical shifts in the care of patients with gastrointestinal (GI) cancers ahead of the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting . Advancements in Colorectal...

In a cobranded episode between Oncology on the Go , hosted by CancerNetwork®, and the American Society for Transplantation and Cellular Therapy (ASTCT)’s program ASTCT Talks , Mitchell E. Horwitz, MD, highlighted key developments and ongoing initiatives related to allogeneic and cord blood transplantations among patients with different hematologic malignancies. The conversation touched upon the im...

Results from the first-in-human, phase 1 MYTHIC trial (NCT04855656) demonstrated that combining the WEE1 inhibitor zedoresertib with the PYKMT1 inhibitor lunresertib achieved an overall response rate (ORR) of 18.5% via RECIST criteria in patients with CCNE1 , FBXW7 , and PPP2R1A -altered cancers.1 In patients with resistant/refractory ovarian cancer, the ORR was 33.3% across all dose levels and 50...

Following the 2026 National ICE-T Conference in Charlotte, North Carolina, Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA, and Barry Paul, MD, spoke with CancerNetwork® about high-level takeaways that emerged during the meeting. They discussed how CAR T-cell therapies, bispecific antibodies, and other novel modalities currently fit into the treatment paradigm across multiple myeloma, leukemia, lymp...